Meridian Bioscience

Meridian Bioscience Financing Cash Flow

The Net Financing Cash Flow of Meridian Bioscience (VIVO) as of Oct 27, 2026 is -34.30 M USD. In the previous year, Net Financing Cash Flow was -31.07 M USD — a change of 10.41% (lower).

Financing Cash Flow

-34.30 MUSD

YoY

10.41%

Last updated:

Net Financing Cash Flow of Meridian Bioscience is 2022 -34.30 M USD. Net Financing Cash Flow of Meridian Bioscience was 2021 -31.07 M USD. It decreases by 10.41% lower compared to the previous year.

The Meridian Bioscience Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2015
-30.74 M USD
Jan 1, 2016
27.21 M USD
Jan 1, 2017
-27.71 M USD
Jan 1, 2018
-27.59 M USD
Jan 1, 2019
14.92 M USD
Jan 1, 2020
-3.56 M USD
Jan 1, 2021
-31.07 M USD
Jan 1, 2022
-34.30 M USD
The Meridian Bioscience Financing Cash Flow history
YEARFinancing Cash FlowYoY
-34.30 MUSD+10.41%
-31.07 MUSD+772.72%
-3.56 MUSD-123.86%
14.92 MUSD-154.08%
-27.59 MUSD-0.43%
-27.71 MUSD-201.84%
27.21 MUSD-188.52%
-30.74 MUSD-3.18%
-31.75 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Net Financing Cash Flow of Meridian Bioscience is -34.30 M USD in 2022.

Net Financing Cash Flow of Meridian Bioscience changed from -31.07 M USD to -34.30 M USD, representing a 10.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Meridian Bioscience

All Key Metrics — Meridian Bioscience